Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epigenetics in chronic lymphocytic leukemia.

Aparna Raval1, John C Byrd, Christoph Plass

  • 1Department of Molecular Virology, Immunology, and Medical Genetics, Division of Human Cancer Genetics, The Ohio State University, Columbus, OH 43210, USA.

Seminars in Oncology
|April 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Blood advances·2026
Same author

Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs.

Blood·2026
Same author

GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer.

Clinical epigenetics·2026
Same author

ID3 deficiency alters chromatin accessibility at DSB sites and enhances vulnerability to HDAC inhibition.

International journal of cancer·2026
Same author

Epigenetic dysregulation of IRF9 drives excessive interferon signaling in COPD.

EMBO molecular medicine·2026
Same author

Happy birthday IJC.

International journal of cancer·2026
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Epigenetic modifications are crucial in cancer, including chronic lymphocytic leukemia (CLL). Understanding epigenetic changes like DNA methylation aids in discovering diagnostic markers and novel therapies for cancer.

Area of Science:

  • Oncology and Molecular Biology
  • Cancer Epigenetics

Background:

  • Epigenetic modifications play a significant role in cancer development, shifting research focus from purely genetic alterations to integrated genetic and epigenetic studies.
  • Chronic lymphocytic leukemia (CLL) research has increasingly incorporated epigenetic aberrations, moving beyond solely examining deleted chromosomal regions.
  • Novel genes silenced by epigenetic mechanisms have been identified in CLL.

Purpose of the Study:

  • To highlight the importance of epigenetic modifications in cancer, particularly in chronic lymphocytic leukemia (CLL).
  • To emphasize the role of understanding DNA methylation and histone modifications in identifying diagnostic markers and therapeutic targets.
  • To underscore the evolving nature of epigenetics and its potential to revolutionize cancer therapeutics.

Main Methods:

Related Experiment Videos

  • Review of accumulated evidence on epigenetic modifications in cancer.
  • Analysis of studies focusing on epigenetic aberrations in Chronic Lymphocytic Leukemia (CLL).
  • Examination of advances in understanding post-translational histone modifications and DNA methylation.

Main Results:

  • Identification of numerous novel genes epigenetically silenced in CLL.
  • Demonstration that understanding epigenetic changes aids in discovering diagnostic markers.
  • Evidence suggests epigenetic insights are beneficial for exploring novel cancer therapies.

Conclusions:

  • Epigenetic modifications are integral to cancer, with significant implications for Chronic Lymphocytic Leukemia (CLL).
  • Advances in DNA methylation and histone modification research offer powerful diagnostic tools and therapeutic avenues.
  • Further exploration of epigenetics in cancer holds the promise of a revolution in cancer treatment.